Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026
Avadel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Avadel Pharmaceuticals stock had an average target of 19.14, with a low estimate of 12 and a high estimate of 22.5.
Price Target: $19.14 (-11.55%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 20, 2025.
Analyst Ratings
The average analyst rating for Avadel Pharmaceuticals stock from 8 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 1 | 1 | 1 | 0 |
| Hold | 1 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 10 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | +3.97% | Nov 20, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $16 → $20 | Hold | Maintains | $16 → $20 | -7.58% | Nov 7, 2025 |
| UBS | UBS | Strong Buy → Hold Downgrades $20 | Strong Buy → Hold | Downgrades | $20 | -7.58% | Oct 28, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $19 | Buy → Hold | Downgrades | $19 | -14.51% | Oct 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $36 → $20 | Strong Buy → Hold | Downgrades | $36 → $20 | -7.58% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
279.84M
from 169.12M
Increased by 65.47%
Revenue Next Year
366.25M
from 279.84M
Increased by 30.88%
EPS This Year
0.20
from -0.51
EPS Next Year
0.83
from 0.20
Increased by 313.31%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 295.2M | 397.2M | ||||
| Avg | 279.8M | 366.3M | ||||
| Low | 261.7M | 338.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 74.5% | 41.9% | ||||
| Avg | 65.5% | 30.9% | ||||
| Low | 54.7% | 20.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.36 | 1.20 | ||||
| Avg | 0.20 | 0.83 | ||||
| Low | 0.11 | 0.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 499.6% | ||||
| Avg | - | 313.3% | ||||
| Low | - | 184.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.